Fundamental Analysis of BIORA THERAPEUTICS INC(NASDAQ:BIOR) stock

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to BIOR. BIOR was compared to 565 industry peers in the Biotechnology industry. BIOR has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, BIOR is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

BIOR had negative earnings in the past year.

BIOR had a negative operating cash flow in the past year.

BIOR had negative earnings in each of the past 5 years.

BIOR had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

BIOR has a Return On Assets of -474.11%. This is amonst the worse of the industry: BIOR underperforms 97.33% of its industry peers.

		Industry Rank	Sector Rank
ROA	-474.11%
ROE	N/A
ROIC	N/A

ROA(3y)-232.13%

ROA(5y)-209.25%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BIOR so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BIOR does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, BIOR has less shares outstanding

BIOR has more shares outstanding than it did 5 years ago.

The debt/assets ratio for BIOR has been reduced compared to a year ago.

2.2 Solvency

BIOR has an Altman-Z score of -87.32. This is a bad value and indicates that BIOR is not financially healthy and even has some risk of bankruptcy.

BIOR's Altman-Z score of -87.32 is on the low side compared to the rest of the industry. BIOR is outperformed by 97.33% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-87.32

ROIC/WACCN/A

WACC3.23%

2.3 Liquidity

BIOR has a Current Ratio of 0.20. This is a bad value and indicates that BIOR is not financially healthy enough and could expect problems in meeting its short term obligations.

The Current ratio of BIOR (0.20) is worse than 97.15% of its industry peers.

BIOR has a Quick Ratio of 0.20. This is a bad value and indicates that BIOR is not financially healthy enough and could expect problems in meeting its short term obligations.

Looking at the Quick ratio, with a value of 0.20, BIOR is doing worse than 96.61% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	0.2
Quick Ratio	0.2

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 90.78% over the past year.

Looking at the last year, BIOR shows a very negative growth in Revenue. The Revenue has decreased by -75.00% in the last year.

BIOR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -87.23% yearly.

EPS 1Y (TTM)90.78%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%87.57%

Revenue 1Y (TTM)-75%

Revenue growth 3Y-87.23%

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

BIOR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.66% yearly.

Based on estimates for the next years, BIOR will show a very strong growth in Revenue. The Revenue will grow by 74.20% on average per year.

EPS Next Y-60.44%

EPS Next 2Y35.07%

EPS Next 3Y20.96%

EPS Next 5Y15.66%

Revenue Next Year-99.17%

Revenue Next 2Y106.59%

Revenue Next 3Y102.82%

Revenue Next 5Y74.2%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BIOR. In the last year negative earnings were reported.

Also next year BIOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

BIOR's earnings are expected to grow with 20.96% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y35.07%

EPS Next 3Y20.96%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for BIOR!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIORA THERAPEUTICS INC

NASDAQ:BIOR (11/18/2024, 8:11:32 PM)

After market: 1.9001 +0.09 (+4.98%)

1.81

-0.31 (-14.62%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap7.86M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-474.11%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.05

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.2
Quick Ratio	0.2
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)90.78%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-60.44%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-75%

Revenue growth 3Y-87.23%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

BIORA THERAPEUTICS INC (BIOR)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens